[IL-6 inhibitors for treatment of rheumatoid arthritis].
Nishimoto
Norihiro
N
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D018450:Disease Progression; D017277:Drug Approval; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis; D007564:Japan; D016032:Randomized Controlled Trials as Topic; D019947:Receptors, Interleukin-6 / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; C502936:tocilizumab